Broadfin Capital, LLC, 10% Owner at PROGENICS PHARMACEUTICALS INC (PGNX), sold 351,300 shares at $9.65 ($3.4M) on 2017-02-07, disclosed to the SEC on 2017-02-09.
Open-market sale of $3.4M PGNX by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.65 | 50,000 | $483K | 14.1% |
| 2 | $9.74 | 100,000 | $974K | 28.6% |
| 3 | $9.66 | 100,000 | $966K | 28.3% |
| 4 | $9.69 | 1,300 | $13K | 0.4% |
| 5 | $9.75 | 100,000 | $975K | 28.6% |
| Total | $9.71 avg | 351,300 |
| $3.4M |
| 100% |
| Filing → |
| BDSI | SELL | 2019-05-14 | $9.0M | — | Filing → |
| REPH | SELL | 2018-05-24 | $1.1M | — | Filing → |
| REPH | SELL | 2018-03-15 | $2.0M | — | Filing → |